91 – 100 of 146
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts
(
- Contribution to journal › Article
-
Mark
Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-β–negative cognitively normal individuals
(
- Contribution to journal › Article
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
- 2020
-
Mark
Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Test–retest repeatability of [18F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
(
- Contribution to journal › Article
-
Mark
Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
(
- Contribution to journal › Article
-
Mark
Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
(
- Contribution to journal › Article
-
Mark
The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
(
- Contribution to journal › Article
-
Mark
Amyloid-β PET and CSF in an autopsy-confirmed cohort
(
- Contribution to journal › Article